现代医药卫生
現代醫藥衛生
현대의약위생
MODERN MEDICINE HEALTH
2015年
4期
488-490,493
,共4页
乳腺肿瘤/治疗%受体,雌激素%受体,孕酮%受体,表皮生长因子%三阴乳腺癌
乳腺腫瘤/治療%受體,雌激素%受體,孕酮%受體,錶皮生長因子%三陰乳腺癌
유선종류/치료%수체,자격소%수체,잉동%수체,표피생장인자%삼음유선암
Breast neoplasms/therapy%Receptors,estrogen%Receptors,progesterone%Receptors,epidermal growth factor%Triple-negative breast cancer
三阴乳腺癌(TNBC),即雌激素受体、孕激素受体、人表皮生长因子受体-2(Her-2)均为阴性的乳腺癌,约占乳腺癌的15.0%~25.0%,具有易复发、易转移和预后差的特点,且不能从内分泌治疗和Her-2靶向药物治疗获益。其治疗为化疗、手术及放疗的综合治疗,有效的靶向治疗正在探索中。该文主要就TNBC的局部治疗、全身治疗及预后进行了综述。
三陰乳腺癌(TNBC),即雌激素受體、孕激素受體、人錶皮生長因子受體-2(Her-2)均為陰性的乳腺癌,約佔乳腺癌的15.0%~25.0%,具有易複髮、易轉移和預後差的特點,且不能從內分泌治療和Her-2靶嚮藥物治療穫益。其治療為化療、手術及放療的綜閤治療,有效的靶嚮治療正在探索中。該文主要就TNBC的跼部治療、全身治療及預後進行瞭綜述。
삼음유선암(TNBC),즉자격소수체、잉격소수체、인표피생장인자수체-2(Her-2)균위음성적유선암,약점유선암적15.0%~25.0%,구유역복발、역전이화예후차적특점,차불능종내분비치료화Her-2파향약물치료획익。기치료위화료、수술급방료적종합치료,유효적파향치료정재탐색중。해문주요취TNBC적국부치료、전신치료급예후진행료종술。
Triple-negative breast cancer (TNBC) means the breast cancer with estrogen receptor,progestrone receptor, human epidermal growth factor receptor 2(Her-2) being negative,accounting for about 15.0%-25.0% of breast cancers. It is charaterized with tending to recrudesce,metastasis and being poor in prognosis,which didit benefit from adjusting Endocrine level and Her-2 targeted drugs. It′s treatment is comprehensive including chemotherapy,surgery and radiotherapy,while the effective targeted therapy is in process. This article focuses on the local and general therapies as well as prognosis.